These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30932446)

  • 41. Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts.
    Balow JE; Ryan JG; Chae JJ; Booty MG; Bulua A; Stone D; Sun HW; Greene J; Barham B; Goldbach-Mansky R; Kastner DL; Aksentijevich I
    Ann Rheum Dis; 2013 Jun; 72(6):1064-70. PubMed ID: 23223423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation.
    Alejandre N; Ruiz-Palacios A; García-Aparicio AM; Blanco-Kelly F; Bermúdez S; Fernández-Sanz G; Romero FI; Aróstegui JI; Ayuso C; Jiménez-Alfaro I; Herrero-Beaumont G; Sánchez-Pernaute O
    Rheumatology (Oxford); 2014 Jun; 53(6):1095-9. PubMed ID: 24501247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post-inflammatory retinal dystrophy in CINCA syndrome.
    Rigante D; Stabile A; Minnella A; Avallone L; Ziccardi L; Bersani G; Stifano G; Compagnone A; Falsini B
    Rheumatol Int; 2010 Jan; 30(3):389-93. PubMed ID: 19424698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Future of IL-1 Targeting in Kidney Disease.
    Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
    Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
    Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
    Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoinflammatory associated vasculitis.
    Ginsberg S; Rosner I; Rozenbaum M; Slobodin G; Zilber K; Boulman N; Kaly L; Awisat A; Jiries N; Beyar-Katz O; Rimar D
    Semin Arthritis Rheum; 2016 Dec; 46(3):367-371. PubMed ID: 27612399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Schnitzlers SyndromeDifferential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra].
    Adam Z; Šedivá A; Koukalová R; Řehák Z; Petrášová H; Szturz P; Adamová Z; Vetešníková E; Pour L; Krejčí M; Sandecká V; Pourová E; Čermáková Z; Ševčíková S; Král Z; Mayer J
    Vnitr Lek; 2016; 62(9):713-727. PubMed ID: 27715073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Periodic fever: From Still's disease to Muckle-Wells syndrome.
    Solís Marquínez MN; García Fernández E; Morís de la Tassa J
    Reumatol Clin (Engl Ed); 2019; 15(5):e39-e40. PubMed ID: 28583784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Reactivation of the cryopyrin-associated periodic syndrome after vaccination in a patient who is a candidate for immunosuppression].
    Fernández-Prada M; Rugeles-Niño J; Suárez-Pérez L; Ruiz-Álvarez M; López-Díaz JB; Fernández-Madera J; Martínez-Ortega C; Huerta-González I
    Rev Esp Quimioter; 2019 Aug; 32(4):379-380. PubMed ID: 31241279
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review.
    Deshayes S; Georgin-Lavialle S; Hot A; Durel CA; Hachulla E; Rouanes N; Audia S; Le Gallou T; Quartier P; Urbanski G; Messer L; Klein S; de Boysson H; Bienvenu B; Grateau G; Aouba A
    J Rheumatol; 2018 Mar; 45(3):425-429. PubMed ID: 29335349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple sclerosis in a patient with cryopyrin-associated autoinflammatory syndrome: Evidence that autoinflammation is the common link.
    Papagoras C; Lampropoulou V; Mavraki E; Chrysanthopoulou A; Deftereos S; Aróstegui JI; Skendros P; Ritis K
    Clin Immunol; 2021 Jun; 227():108750. PubMed ID: 33945870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
    Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
    Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Case of Amyloidosis Caused by Sporadic Muckle-Wells Syndrome: Response to Treatment With Anakinra.
    İlgen U; Küçükşahin O; Erdoğmuş Ş; Nergizoğlu G
    J Clin Rheumatol; 2018 Aug; 24(5):290-291. PubMed ID: 29239931
    [No Abstract]   [Full Text] [Related]  

  • 57. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
    Savic S; McDermott MF
    Nat Rev Rheumatol; 2009 Oct; 5(10):529-30. PubMed ID: 19798026
    [No Abstract]   [Full Text] [Related]  

  • 58. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
    Lipsker D; Lenormand C
    Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Corneal response to canakinumab in cryopyrin associated periodic fever syndrome.
    Tsatsos M; Hawkin PN; Hossain P
    Br J Ophthalmol; 2013 Aug; 97(8):1081-2. PubMed ID: 23740963
    [No Abstract]   [Full Text] [Related]  

  • 60. Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome.
    Kanariou M; Dracou C; Spanou K; Möller J; Rösen-Wolff A; Schuster V; Roesler J
    Klin Padiatr; 2009; 221(6):379-81. PubMed ID: 19890791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.